Lilly paid $7.8 billion for Centessa Pharmaceuticals. Centessa had no revenue. It had one Phase 2 drug — cleminorexton, an orexin receptor agonist — and a portfolio of earlier-stage programs in rare neurological disease. What Lilly bought, in the most precise sense, was the future: a probability-weighted estimate of what cleminorexton would be worth if it cleared Phase 3 in narcolepsy, received FDA approval, and achieved commercial adoption in a disease with no adequate treatment. That future value, translated into a present-day acquisition price, is what I mean by the speculative market cap.
Every major biopharma acquisition in the 2026 deal cycle is an acquisition of speculative market cap — the portion of enterprise value that reflects future pipeline potential rather than current or near-term revenues. Merck paid $6.7 billion for an asset that had never been produced at commercial scale and whose pivotal trial had not started. Gilead paid up to $5 billion for an ADC platform company whose programs were in early clinical or preclinical development. AbbVie paid $1.2 billion for a psychedelic-derived antidepressant candidate that was Gilgamesh’s lead compound and first-in-human data anchor. These are not acquisitions of businesses. They are acquisitions of bets.
The legal architecture of a deal built on speculative market cap acquisition differs from a commercial franchise acquisition in four specific ways: the diligence, the consideration structure, the representations and warranties, and the post-closing risk allocation. And the CLO’s role — in protecting the value that justified the premium and managing the liability when that value doesn’t materialize — is specific and consequential in ways that standard M&A legal work does not fully capture.
The speculative market cap is the deal.
— John LaRocca
Founding Editor | LaRocca Advisory Group
■ DEAL DISSECTION
The Speculative Market Cap: How Biotech Deals Are Priced on Future Value — and What That Means for the CLO
Format: Deal Dissection | Covers: pipeline valuation, CVR architecture, diligence of speculative assets, MAC provisions in speculative deals, post-closing value realization, CLO’s role in protecting speculative premium
What the Speculative Market Cap Actually Is
A biotech company’s market capitalization has two components. The first is the value of products that are approved, generating revenue, and whose cash flows can be modeled with reasonable confidence. The second is the value the market assigns to products that are in development — Phase 1, Phase 2, Phase 3, or even preclinical — weighted by the probability that they succeed, discounted to the present, and adjusted for the time it will take to commercialize them.
The second component is the speculative market cap. For a company like Centessa before its acquisition, essentially the entire market capitalization was speculative. Centessa had no approved products, no revenue, and no near-term path to cash flow. Its enterprise value was a pure present-value calculation of the probability that cleminorexton works, gets approved, and generates meaningful commercial revenue against a competitive landscape of other sleep disorder therapies.
For a company like Apellis before its acquisition by Biogen, the speculative market cap was smaller but still material. Apellis had two approved products generating $689 million in combined 2025 revenue — that is the revenue component. But Apellis also had pipeline programs, label expansion opportunities for Syfovre beyond geographic atrophy, and the prospect of additional complement pathway assets in development. Biogen paid $5.6 billion plus a $4-per-share CVR. The revenue component of Apellis was worth a specific multiple. The CVR — contingent on Syfovre achieving defined commercial milestones — was the mechanism for paying for the speculative component.
Understanding where the speculative market cap sits in any specific deal is the CLO’s first analytical task. It tells you where the deal risk is concentrated, what the right legal architecture looks like, and what the post-closing liability exposure is if the speculative value does not materialize.
Why the Legal Architecture Differs
A deal built primarily on current revenue — a commercial franchise acquisition — has a relatively straightforward legal risk profile. The assets are generating cash. The revenue can be audited. The customer relationships are contractual. The representations and warranties cover what the company has already done, and the RWI policy covers the risk that those representations are wrong.
A deal built primarily on speculative market cap has a different risk profile. The representations and warranties cover what the company has done in the development program — what it said to FDA, how it conducted the clinical trials, what it knew about the safety profile — but they do not and cannot guarantee that the program will succeed. No seller can represent that its Phase 2 drug will clear Phase 3. The speculative value itself is outside the representation scope.
That gap — between what the legal documentation covers and where the deal value actually lives — is where post-closing disputes are born. Three legal mechanisms close it:
Contingent Value Rights
The CVR is the most common mechanism for paying for speculative value. Rather than incorporating the speculative premium into the upfront consideration, the acquirer pays a base price for the confirmed value and a contingent payment — triggered by clinical milestones, regulatory approvals, or commercial performance — for the speculative value. Lilly’s acquisition of Centessa included a $9-per-share CVR across three regulatory milestones for cleminorexton. Biogen’s acquisition of Apellis included a $4-per-share CVR tied to Syfovre commercial performance. Merck’s acquisition of Prometheus Biosciences in 2023 included CVRs tied to Phase 3 data readouts.
The CVR is technically demanding as a legal instrument. The definition of the milestone — what exactly triggers payment — is negotiated with precision because it is the question every subsequent dispute will turn on. ‘FDA approval of cleminorexton for narcolepsy type 1’ is unambiguous. ‘Commercially reasonable efforts to achieve FDA approval of cleminorexton for narcolepsy type 1’ is a standard that generates litigation when the acquirer’s commercial priorities shift. The CLO’s role in CVR negotiation is to make the milestone definition specific enough that it cannot be disputed and the development obligation standard specific enough that it cannot be evaded.
Development Obligation Covenants
When the acquirer commits to pursue the speculative value through a CVR, it also typically commits to pursue it with a defined level of effort. The development obligation covenant specifies how hard the acquirer must try: what resources it must deploy, what timeline it must follow, and what commercial decisions it can make about deprioritizing the acquired program in favor of its own pipeline.
Development obligation litigation is the predictable back end of speculative market cap acquisitions. The seller negotiates ‘best efforts’ or ‘commercially reasonable efforts’ and believes the CVR is genuinely contingent on the acquirer’s good-faith pursuit of the milestone. The acquirer deploys the asset against its internal portfolio priorities and two years later decides the program is no longer competitive. The CVR holders sue, alleging breach of the development obligation. The litigation turns on what ‘commercially reasonable efforts’ meant in the specific commercial context at the time the decision was made. Cases on this issue include Akorn v. Fresenius (MAC litigation arising from the speculative acquisition context) and multiple CVR disputes involving Sanofi, AstraZeneca, and BMS.
MAC Provisions Calibrated to Speculative Risk
Material adverse change provisions in speculative market cap acquisitions must account for the specific risks of pipeline programs — risks that a commercial franchise acquisition does not face. A Phase 3 clinical failure between signing and closing is a material adverse change. A Complete Response Letter from FDA is a material adverse change. An unexpected safety finding in the clinical database is a material adverse change.
The MAC definition in a speculative acquisition must be carefully calibrated to exclude general clinical development risk — the fact that Phase 3 trials fail more than half the time is background risk that the acquirer accepted when it signed at the speculative price — while capturing specific events that change the fundamental value of what was acquired. Drafting that distinction requires understanding both the regulatory pathway and the scientific basis for the valuation.
The Diligence Problem: How Do You Diligence Something That Doesn’t Exist Yet?
Standard M&A diligence evaluates what a company has. It reviews contracts, financial statements, regulatory submissions, litigation history, and IP chain of title. It assesses whether the company’s representations about what exists are accurate.
Diligencing a speculative market cap requires a different question: whether the company’s representations about the probability of what will exist are accurate. That question requires scientific expertise, regulatory judgment, and competitive landscape assessment that standard M&A legal teams do not carry in-house.
Five diligence items belong on every protocol for a speculative market cap acquisition:
• The regulatory submission history and FDA relationship. What has the company said to FDA in Type B and Type C meetings? What has FDA said back? A company that has received signals from FDA about concerns with its regulatory approach — concerns that are captured in meeting minutes that are not public but are discoverable in diligence — is a company whose speculative probability is lower than its market cap implies.
• The clinical data package as of signing. Not the published results. The full clinical data package, including adverse event narratives, protocol deviations, site audit findings, and statistical analysis plans. A Phase 2 that looks clean in the press release may have material data integrity issues in the underlying dataset that the acquirer’s clinical scientists need to evaluate.
• The competitive landscape for the indication. The speculative market cap assumes the asset has commercial value if it works. But commercial value depends on the competitive context. If three other programs in the same mechanism are six months behind in Phase 3, the market opportunity is different from what the valuation implied.
• The manufacturing readiness for commercial scale. A Phase 2 program acquired at a speculative premium has a manufacturing development obligation — the acquirer must take the process from Phase 2 supply to commercial scale before the asset can generate the revenue that justifies the acquisition price. The cost and timeline of that development are speculative costs that must be modeled against the speculative value.
• The key person dependency. The principal investigators who ran the Phase 2, the clinical scientists who designed the study, and the regulatory strategists who managed the FDA relationship are the institutional knowledge base for the speculative value. If they leave at closing — which is structurally likely when their equity vests — the probability of the speculative value being realized decreases.
The Post-Closing Risk: When the Speculative Value Doesn’t Materialize
The speculative market cap is a probability-weighted estimate. By definition, a meaningful percentage of acquisitions built on speculative value will see that value fail to materialize. Phase 3 trials fail. FDA issues Complete Response Letters. Commercial launches underperform projections. When speculative value fails to materialize post-closing, three legal situations arise that the CLO must be prepared for.
CVR Disputes
When the milestone that triggers CVR payment is not met — or when it is met but the acquirer disputes whether it was met on the definition’s terms — the CVR holders have a claim. CVR litigation is complex and expensive. The CVR holders are often former shareholders who organized post-closing into a litigation trust. The acquirer’s defense is that it pursued the milestone with the required level of effort and the outcome was beyond its control. The key evidence: the development obligation covenant, every internal document about the acquired program’s prioritization, and every communication between the acquirer’s commercial and R&D teams about the decision to deprioritize or accelerate.
Securities Fraud Claims Based on Pre-Closing Misrepresentation of Speculative Value
When a public company’s speculative market cap collapses — after a Phase 3 failure or a CRL — the securities class action attorneys examine whether the company’s pre-closing public statements about the program’s prospects were accurate. The question is not whether management believed the drug would work. The question is whether management had information that made the program’s prospects materially different from what was represented to investors. Under FDA’s new real-time CRL publication regime, the company’s public statements are compared directly against FDA’s own assessment. Any gap produces a securities fraud allegation.
Breach of Development Obligation
The development obligation covenant means little without an enforcement mechanism. CVR holders who believe the acquirer breached its obligation to pursue the milestone must file suit and prove that the acquirer’s resource allocation decisions fell below the contractual standard. The litigation is fact-intensive and expensive. The CLO who maintained documentation of every resource allocation decision — the internal approval for the R&D budget, the portfolio prioritization meeting minutes, the clinical development plan updates — is the CLO who is prepared to defend against this claim. The CLO who let the documentation discipline slip is defending against it from memory.
WORKSTREAM 1 IMMEDIATE
Define the Speculative Value Component Before Negotiating the Consideration Structure
Before any consideration structure is proposed or accepted in a speculative market cap acquisition, the CLO should require a documented analysis of where the speculative value sits, what it represents as a percentage of total enterprise value, and what legal mechanisms are available to manage the risk that it does not materialize. The analysis drives everything else: whether a CVR is the right structure and what its milestone definition should be; whether the development obligation covenant needs to be specific enough to be enforceable; whether RWI coverage should be sized to include speculative asset risk; and whether the MAC definition is calibrated to exclude general clinical development risk while capturing specific events that change the fundamental value of the acquired program. A deal team that arrives at the consideration structure before this analysis is complete is pricing the speculative component on intuition rather than legal architecture.
BUSINESS IMPACT: A consideration structure that does not match the risk profile of the speculative value it is paying for produces post-closing disputes that were avoidable. The CVR definition, the development obligation standard, and the MAC carve-outs must be designed together, not negotiated piecemeal.
WORKSTREAM 2 NEAR-TERM
Build the Speculative Asset Diligence Protocol and Run It Before Signing
The five diligence items identified above — regulatory submission history, full clinical data package, competitive landscape, manufacturing readiness, and key person dependency — must be on every diligence checklist for any acquisition where the speculative market cap exceeds 30% of the enterprise value. That threshold covers essentially every Phase 2/3 biotech acquisition in the current market. Each item requires different expertise: regulatory affairs counsel for the FDA meeting history, clinical scientists for the data package, competitive intelligence for the landscape assessment, manufacturing subject matter experts for the scale-up risk, and the employment diligence team for the key person analysis. Assigning these items to the standard M&A legal team without supplementing with the relevant expertise is guaranteeing incomplete diligence.
BUSINESS IMPACT: A Phase 3 failure that could have been predicted from FDA meeting minutes the acquirer never reviewed is a post-closing value destruction event that was avoidable with adequate diligence. At a $7 billion acquisition price, the cost of supplemental clinical and regulatory diligence is immaterial relative to the risk being assessed.
WORKSTREAM 3 STRATEGIC
Maintain the Development Obligation Documentation Program From Signing Through CVR Resolution
Every CVR with a development obligation covenant requires an ongoing documentation program that runs from signing through the final milestone resolution — potentially years. The program covers: quarterly documentation of resource allocation to the acquired program (R&D budget, headcount, clinical development plan progress); records of every portfolio prioritization decision that affects the acquired program; documentation of every material development decision (advancing to Phase 3, expanding the indication, modifying the endpoint) with the rationale for each; and communication records with key investigators, CDOs, and regulatory consultants. The CLO does not run this program. The clinical development team does. But the CLO designs the documentation protocol and ensures it is running from Day 1 of closing. A program that starts at Year 2 when the CVR dispute is filed is a program that has already lost the documentation that mattered most.
BUSINESS IMPACT: CVR litigation turns on what the acquirer decided about the acquired program and when. The acquirer that documented its development decisions contemporaneously with a clear rationale for each has a defensible record. The one that reconstructs its decision-making from memory two years later does not.
“The speculative market cap is what most pharma M&A deals are actually about. The legal architecture of speculative value — how you structure the consideration, how you diligence what does not yet exist, how you protect the value that justified the premium — is the CLO’s contribution to the deal that matters most.”
PRACTITIONER TEMPLATES — NOW AVAILABLE
The Speculative Market Cap CLO Toolkit
Three commercial templates built on the analytical framework in this issue — ready to use in your next transaction.
Template 1: Speculative Value Analysis Template | $147
Quantify the speculative component, calculate risk-adjusted value, design CVR milestone definitions, and calibrate the MAC definition.
Template 2: Speculative Asset Diligence Protocol | $197
Five complete workstreams — regulatory submission history, full clinical data package, competitive landscape, manufacturing readiness, and key person dependency — each with scope, key questions, red flags, and document request list.
Template 3: Development Obligation Documentation Program | $147
Quarterly documentation records, material development decision forms, CVR milestone determination records, and litigation hold protocol — running from Day 1 of closing through final CVR resolution.
Bundle all three: $397 (save $94)
Available at https://laroccaadvisory.gumroad.com/
ABOUT THE AUTHOR
John LaRocca is a pharma and biotech attorney with 26 years of in-house experience, including CLO/GC tenures at Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. He is the founding partner of LaRocca Advisory Group, a boutique fractional CLO services firm. The GC Playbook reflects his personal views and does not constitute legal advice.
© 2026 The GC Playbook | All rights reserved | Not for redistribution without permission


